Published in Cephalalgia on February 11, 2010
CGRP receptor antagonism and migraine. Neurotherapeutics (2010) 0.98
Chemical mediators of migraine: preclinical and clinical observations. Headache (2011) 0.84
The potent calcitonin gene-related peptide receptor antagonist, telcagepant, does not affect nitroglycerin-induced vasodilation in healthy men. Br J Clin Pharmacol (2011) 0.77
Opposite reactivity of meningeal versus cortical microvessels to the nitric oxide donor glyceryl trinitrate evaluated in vivo with two-photon imaging. PLoS One (2014) 0.75
Comments on 'Calcitonin gene-related peptide (CGRP) levels during glyceryl trinitrate (GTN)-induced headache in healthy volunteers'. Cephalalgia (2010) 0.75
The role of calcitonin gene-related peptide in peripheral and central pain mechanisms including migraine. Pain (2017) 0.75
The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol (2011) 9.40
New appendix criteria open for a broader concept of chronic migraine. Cephalalgia (2006) 5.97
Understanding the biologic basis of migraine. N Engl J Med (1994) 5.25
Cerebral autoregulation. Cerebrovasc Brain Metab Rev (1990) 5.13
Epidemiology of headache in a general population--a prevalence study. J Clin Epidemiol (1991) 4.78
Autoregulation of brain circulation in severe arterial hypertension. Br Med J (1973) 4.11
Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol (1990) 3.25
The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol (1993) 3.07
The International Classification of Headache Disorders, 2nd Edition (ICHD-II)--revision of criteria for 8.2 Medication-overuse headache. Cephalalgia (2005) 2.86
A yeast and a human CCAAT-binding protein have heterologous subunits that are functionally interchangeable. Cell (1988) 2.84
CGRP may play a causative role in migraine. Cephalalgia (2002) 2.40
Questionnaire versus clinical interview in the diagnosis of headache. Headache (1991) 2.36
Migraine with aura and migraine without aura: an epidemiological study. Cephalalgia (1992) 2.33
Delayed hyperemia following hypoperfusion in classic migraine. Single photon emission computed tomographic demonstration. Arch Neurol (1988) 2.30
Migraine without aura and migraine with aura are distinct clinical entities: a study of four hundred and eighty-four male and female migraineurs from the general population. Cephalalgia (1996) 2.29
Neuropeptide Y co-exists and co-operates with noradrenaline in perivascular nerve fibers. Regul Pept (1984) 2.27
Regional cerebral blood flow in man determined by the initial slope of the clearance of intra-arterially injected 133Xe. Stroke (1974) 2.26
Thrombolysis outcomes in acute ischemic stroke patients with prior stroke and diabetes mellitus. Neurology (2011) 2.24
Mechanical properties of rat cerebral arteries as studied by a sensitive device for recording of mechanical activity in isolated small blood vessels. Acta Physiol Scand (1983) 2.20
Impact of headache on sickness absence and utilisation of medical services: a Danish population study. J Epidemiol Community Health (1992) 2.12
Migraine pain associated with middle cerebral artery dilatation: reversal by sumatriptan. Lancet (1991) 2.11
Eletriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan. Eletriptan Steering Committee. Neurology (2000) 2.10
Focal hyperemia followed by spreading oligemia and impaired activation of rCBF in classic migraine. Ann Neurol (1981) 2.03
Discontinuation of medication overuse in headache patients: recovery of therapeutic responsiveness. Cephalalgia (2006) 2.01
Phosphorylation regulates in vivo interaction and molecular targeting of serine/arginine-rich pre-mRNA splicing factors. J Cell Biol (1999) 2.00
Symptomatic and nonsymptomatic headaches in a general population. Neurology (1992) 1.99
The genetic spectrum of a population-based sample of familial hemiplegic migraine. Brain (2006) 1.97
Prevalence and sex-ratio of the subtypes of migraine. Int J Epidemiol (1995) 1.96
Increased familial risk and evidence of genetic factor in migraine. BMJ (1995) 1.96
A nosographic analysis of the migraine aura in a general population. Brain (1996) 1.91
Timing and topography of cerebral blood flow, aura, and headache during migraine attacks. Ann Neurol (1990) 1.87
Cerebral blood flow velocities are reduced during attacks of unilateral migraine without aura. Cephalalgia (1995) 1.82
Premonitory symptoms in migraine: an electronic diary study. Neurology (2003) 1.81
Release of histamine from dural mast cells by substance P and calcitonin gene-related peptide. Cephalalgia (1997) 1.78
Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann Neurol (1988) 1.77
Human in vivo evidence for trigeminovascular activation in cluster headache. Neuropeptide changes and effects of acute attacks therapies. Brain (1994) 1.72
Calcitonin gene-related peptide is released from capsaicin-sensitive nerve fibres and induces vasodilatation of human cerebral arteries concomitant with activation of adenylyl cyclase. Cephalalgia (1996) 1.69
Improved description of the migraine aura by a diagnostic aura diary. Cephalalgia (1994) 1.68
Dilation by CGRP of middle meningeal artery and reversal by sumatriptan in normal volunteers. Neurology (2010) 1.66
Calcitonin gene-related peptide: functional role in cerebrovascular regulation. Proc Natl Acad Sci U S A (1986) 1.65
Pressure-controlled palpation: a new technique which increases the reliability of manual palpation. Cephalalgia (1995) 1.64
Headache induced by a nitric oxide donor (nitroglycerin) responds to sumatriptan. A human model for development of migraine drugs. Cephalalgia (1996) 1.62
Double-blind, randomized, placebo-controlled study of oral, high-dose methylprednisolone in attacks of MS. Neurology (1998) 1.62
Monitoring tissue oxygen availability with near infrared spectroscopy (NIRS) in health and disease. Scand J Med Sci Sports (2001) 1.60
Subcutaneous sumatriptan during the migraine aura. Sumatriptan Aura Study Group. Neurology (1994) 1.59
Evidence of qualitatively altered nociception in patients with fibromyalgia. Arthritis Rheum (1997) 1.58
The concept of coupling blood flow to brain function: revision required? Ann Neurol (1987) 1.58
Presentation of a new instrument: the diagnostic headache diary. Cephalalgia (1992) 1.57
Muscle palpation with controlled finger pressure: new equipment for the study of tender myofascial tissues. Pain (1994) 1.54
Interrelations between migraine and tension-type headache in the general population. Arch Neurol (1992) 1.53
Effect of inhibition of nitric oxide synthase on chronic tension-type headache: a randomised crossover trial. Lancet (1999) 1.52
Increased risk of migraine with typical aura in probands with familial hemiplegic migraine and their relatives. Eur J Neurol (2003) 1.49
Diagnosis and management of migraine. BMJ (1996) 1.47
Pharmacological characterization of adrenergic alpha and beta receptors mediating the vasomotor responses of cerebral arteries in vitro. Circ Res (1974) 1.46
Botulinum toxin in headache treatment: the end of the road? Cephalalgia (2006) 1.46
The effect of intracarotid epinephrine, norepinephrine, and angiotensin on the regional cerebral blood flow in man. Neurology (1972) 1.46
Neuropeptide Y potentiates the effect of various vasoconstrictor agents on rabbit blood vessels. Br J Pharmacol (1984) 1.46
Nitroglycerin-induced headache is not dependent on histamine release: support for a direct nociceptive action of nitric oxide. Cephalalgia (1994) 1.44
Possible mechanisms of action of nitric oxide synthase inhibitors in chronic tension-type headache. Brain (1999) 1.43
Pharmacological analysis of 5-hydroxytryptamine receptors in isolated intracranial and extracranial vessels of cat and man. Circ Res (1978) 1.42
Autonomic nerves, mast cells, and amine receptors in human brain vessels. A histochemical and pharmacological study. Brain Res (1976) 1.42
Determination of the luminal diameter of the radial artery in man by high frequency ultrasound: a methodological study. Ultrasound Med Biol (1990) 1.41
The CGRP-antagonist, BIBN4096BS does not affect cerebral or systemic haemodynamics in healthy volunteers. Cephalalgia (2005) 1.39
The International classification of headache disorders, 2nd edn (ICDH-II). J Neurol Neurosurg Psychiatry (2004) 1.39
Evaluation of pericranial myofascial nociception by pressure algometry. Reproducibility and factors of variation. Cephalalgia (1992) 1.39
Exteroceptive suppression of temporal muscle activity is normal in chronic tension-type headache and not related to actual headache state. Cephalalgia (1996) 1.39
Myofibre damage in human skeletal muscle: effects of electrical stimulation versus voluntary contraction. J Physiol (2007) 1.38
[Are psychiatric diseases brain diseases?]. Ugeskr Laeger (1999) 1.38
[Decreased pain threshold and tolerance in patients with chronic tension headache]. Ugeskr Laeger (1997) 1.38
Pressure-sensitive devices. Pain (1995) 1.38
[Sumatriptan (Imigran) to patients with hemiplegic migraine?]. Ugeskr Laeger (1992) 1.38
Resource allocation to brain research in Europe (RABRE). Eur J Neurosci (2006) 1.34
Neuropeptide Y potentiates noradrenaline-evoked vasoconstriction: mode of action. J Pharmacol Exp Ther (1985) 1.34
A population-based study of familial hemiplegic migraine suggests revised diagnostic criteria. Brain (2002) 1.34
Evidence of a genetic factor in migraine with aura: a population-based Danish twin study. Ann Neurol (1999) 1.33
Intravenous nitroglycerin as an experimental model of vascular headache. Basic characteristics. Pain (1989) 1.31
Perivascular peptides relax cerebral arteries concomitant with stimulation of cyclic adenosine monophosphate accumulation or release of an endothelium-derived relaxing factor in the cat. Neurosci Lett (1985) 1.29
Delayed inflammation in rat meninges: implications for migraine pathophysiology. Brain (2001) 1.29
Immunohistochemical localization of a vasodilatory polypeptide (VIP) in cerebrovascular nerves. Brain Res (1976) 1.27
A non-selective (amitriptyline), but not a selective (citalopram), serotonin reuptake inhibitor is effective in the prophylactic treatment of chronic tension-type headache. J Neurol Neurosurg Psychiatry (1996) 1.27
Quantitative evaluation of normal and pathologic cerebral blood flow regulation to perfusion pressure. Changes in man. Arch Neurol (1973) 1.25
Sporadic hemiplegic migraine. Cephalalgia (2004) 1.25
The stable pyrimidines UDPbetaS and UTPgammaS discriminate between the P2 receptors that mediate vascular contraction and relaxation of the rat mesenteric artery. Br J Pharmacol (2000) 1.23
Assessment of demyelination, edema, and gliosis by in vivo determination of T1 and T2 in the brain of patients with acute attack of multiple sclerosis. Magn Reson Med (1989) 1.23
Calcitonin gene-related peptide (CGRP): perivascular distribution and vasodilatory effects. Regul Pept (1986) 1.22
Substance P: immunohistochemical localization and effect upon cat pial arteries in vitro and in situ. J Physiol (1981) 1.22
Nitric oxide supersensitivity: a possible molecular mechanism of migraine pain. Neuroreport (1993) 1.22
Amine mechanisms in the cerebral circulation. Pharmacol Rev (1976) 1.21
Regional cerebral blood flow during migraine attacks by Xenon-133 inhalation and emission tomography. Brain (1984) 1.20
Neurogenic mechanisms in the cerebrovascular bed. Autonomic nerves, amine receptors and their effects on cerebral blood flow. Acta Physiol Scand Suppl (1975) 1.19
The effects of PaCO2 on regional cerebral blood flow and internal carotid arterial pressure during carotid clamping. Anesthesiology (1971) 1.18
Neuropeptide Y: cerebrovascular innervation and vasomotor effects in the cat. Neurosci Lett (1983) 1.17
The peptidergic innervation of the human superficial temporal artery: immunohistochemistry, ultrastructure, and vasomotility. Peptides (1995) 1.17
The relative role of genetic and environmental factors in migraine without aura. Neurology (1999) 1.17